Final height and body mass index after treatment for childhood acute lymphoblastic leukemia
Background: Newer and more agressive forms of chemotherapy and newer protocols in the treatment have increased the survival rate of children with malignancies. Improved survival rates in children treated for acute lymphoblastic leukemia have focused attention on late effects including disorders of growth and puberty, and development of overweight or obesity.
Methods: The height and weight expressed as body mass index (BMI) of 47 patients (29 girls, 18 boys) long-term survivors of childhood lymphoblastic leukemia was retrospectively analyzed. Height standard deviation score (HSDS) according to Tanner and body mass index standard deviation scores (BMISDS) before treatment and at follow-up were calculated. At the time of analysis all patients remained in first remission. Twenty-eight patients had cranial radiation with 12–18 Gy and 15 with 20–30 Gy. Four patients had no radiotherapy. All patients were treated with standard chemotherapy including intrathecal Methotrexat. Mean age (SD) at the diagnosis was 5 5/12 (3 2/12) years, range (5/12 – 12 5/12) and at the time of evaluation 17 11/12 (3 9/12) years, range (10 1/12 – 31 6/12).
Results: We observed significant decrease in HSDS from diagnosis to the final height in both radiation groups (p < 0.01) but the decrement in final height was similar with both radiation dose regimens. The decrement in final height SDS was greater in patients treated at a younger age (Pearson, p < 0.01). Girls treated with higher radiation dose (20–30 Gy) were more severely affected than boys. In both radiation dose treatment groups there was a significant increase in BMISDS between diagnosis and final height (p < 0.0001) with no significant difference between treatment groups. Menarche occurred earlier in girls than normal with no significant difference between both radiation dose regimens.
Conclusions: We observed significant deterioration in HSDS and increment in BMISDS regardless to the radiation dose.
Sklar C, Mertens A, Walter A, Mitchell D, Nesbit M, O’Leary M, et al. Final height after treatment for childhood acute lymphoblastic leukemia: Comparison of no cranial irradiation with 1800 and 2400 centigreys of cranial irradiation. J Pediatr 1993; 123: 59–64.
Stubberfield TG, Byrne GC, Jones TW. Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood. J Pediatr Hematol Oncol 1995; 17: 167–71.
Uruena M, Stanhope R, Chessels JM, Leiper AD. Impaired pubertal growth in acute lymphoblastic leukaemia. Arch Dis Child 1991; 66: 1403–7.
Ogilvy-Stuart AL, Clayton PE, Shalet SM. Cranial irradiation and early puberty. J Clin Endocrinol Metab 1994; 78: 1282–6.
Leiper AD, Stanhope R, Kitching P, Chessells JM. Precocious and premature puberty associated with treatment of acute lymphoblastic leukaemia. Arch Dis Child 1987; 62: 1107–12.
Moëll C, Marky I, Hovi L, Kristinsson J, Rix M, Moe PJ, et al. Cerebral irradiation causes blunted pubertal growth in girls treated for acute leukemia. Med Pediatr Oncol 1994; 22: 375–9.
Oberfield SE, Soranno D, Nirenberg A, Heller G, Allen JC, David R, et al. Age at onset of puberty following high-dose central nervous system radiation therapy. Arch Pediatr Adolesc Med 1996; 150: 589–92.
Sainsbury CPQ, Newcombe RG, Hughes IA. Weight gain and height velocity during prolonged first remission from acute lymphoblastic leukaemia. Arch Dis Child 1985; 60: 832–6.
Van Dongen-Melman JEWM, Hoekken-Kolega ACS, Hählen K, De Groot A, Tromp CG, Egeler RM. Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Pediatr Res 1995; 38: 86–90.
Davies HA, Didcock E, Didi M, Ogilvy-Stuart A, Wales JKH, Shalet SM. Growth, puberty and obesity after treatment for leukaemia. Acta Paediatr Suppl 1995; 411: 45–50.
Groot-Loonen JJ, Otten BJ, van’t Hof MA, Lippens RJJ, Stoelinga GBA. Influence of treatment modalities on body weight in acute lymphoblastic leukemia. Med Pediatr Oncol 1996; 27: 92–7.
Odame I, Reilly JJ, Gibson BES, Donaldson MDC. Patterns of obesity in boys and girls after treatment for acute lymphoblastic leukaemia. Arch Dis Child 1994; 71: 147–9.
Warner JT, Gregory JW, Webb DKH. Patterns of obesity in boys and girls after treatment for acute lymphoblastic leukaemia. Arch Dis Child 1995; 72: 97.
Tanner JM, Whitehouse RH, Takaishi M. Standards for birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. Part I. Arch Dis Child 1966; 41: 454–71.
Tanner JM, Whitehouse RH, Takaishi M. Standards for birth to maturity for height, weight, height velocity and weight velocity: British children, 1965. Part II. Arch Dis Child 1966; 41: 613–35.
Tanner JM, Goldstein H, Whitehouse RH. Standards for children’s height ages 2–9 years allowing for height of parents. Arch Dis Child 1970; 45: 755–7.
Rolland-Cachera MF, Cole TJ, Sempé M, Tichet J, Rossignol C, Charraud A. Body mass index variations: centiles from birth to 87 years. Eur J Clin Nutr 1991; 45: 13–21.
Katz JA, Pollock BH, Jacaruso D, Morad A. Final attained height in patients successfully treated for childhood acute lymphoblastic leukemia. J Pediatr 1993; 123: 546–52.
Ogilvy-Stuart AL, Shalet SM. Growth and puberty after growth hormone treatment after irradiation for brain tumours. Arch Dis Child 1995; 73: 141–6.
Crownee EC, Moore C, Wallace WHB, Ogilvy-Stuart AL, Addison GM, Morris-Jones PH. A novel variant of growth hormone (GH) insufficiency following low dose cranial irradiation. Clin Endocrinol 1992; 36: 59–68.
Holm K, Nysom K, Hertz H, Müller J. Normal final height after treatment for acute lymphoblastic leukemia without irradiation. Acta Paediatr 1994; 83: 1287–90.
Clayton PE, Morris-Jones PH, Shalet SM, Price DA. Growth in children treated for acute lymphoblastic leukaemia. Lancet 1988; 2: 460–2.
Thun-Hohenstein, Frisch H, Schuster E. Growth after radiotherapy and chemotherapy in children with leukemia or lymphoma. Horm Res 1992; 37: 91–5.
Mohinke K, Dörfell W, Timme J, Kluba U, Aumann V, Vorwerk P, Mittler U. Final height and puberty in 40 patients after antileukaemic treatment during childhood. Eur J Pediatr 1997; 156: 272–6.
Davies HA, Didcock E, Didi M, Ogilvy-Stuart A, Wales JKH, Shalet SM. Disproportionate short stature after cranial irradiation and combination chemotherapy for leukaemia. Arch Dis Child 1994; 70: 472–5.
De Boer H, Blok GJ, Van Veen VA. Clinical aspects of growth hormone deficiency in adults. Endocrin Rev 1995; 16: 63–86.
Sklar C, Sarafoglou K, Whittam E. Efficacy of insuline-like growth factor binding protein 3 in predicting the growth hormone response to provocative testing in children treated with cranial irradiation. Acta Endocrinol 1993; 129: 511–5.
Brennan BMD, Rahim A, Mackie EM, Eden OB, Shalet SM. Growth hormone status in adults treated for acute lymphoblastic leukaemia in childhood. Clin Endocrinol 1998; 48: 777–83.
Ross JA, Oeffinger KC, Davies SM, Martens AC, Langer EK, Kiffmeyer WR, et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. J Clin Oncol 2004; 22: 3558–62.
Warner JT, Bell W, Webb DKH, Gregory JW. Relationship between cardiopulmonary response to exercise and adiposity in survivors of childhood malignancy. Arch Dis Child 1997; 76: 298–303.
Jenney MEM, Faragher EB, Morris Jones PH, Woodcock A. Lung function and exercise capacity in survivors of childhood leukaemia. Med Ped Oncol 1995; 24: 222–30.
Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of Doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808–15.
Reilly JJ, Ventham JC, Ralston JM, Donaldson M, Gibson B. Reduced energy expenditure in preobese children treated for acute lymphoblastic leukemia. Pediatr Res 1998; 44: 557–62.
Warner JT, Bell W, Webb DK, Gregory JW. Daily energy expenditure and physical activity in survivors in childhood malignancy. Pediatr Res 1998; 43: 607–13.
Talvensaari KK, Lanning M, Tapainen P, Knip M. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Endocrinol Metab 1996; 81: 3051–5.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.